Kane Biotech Inc.
KNE.V
TSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -92.97% | 219.69% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -92.97% | 219.69% | |||
| Cost of Revenue | -79.41% | 69.45% | |||
| Gross Profit | -211.15% | 147.51% | |||
| SG&A Expenses | -84.62% | 181.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -80.00% | 63.06% | |||
| Operating Income | 75.39% | -38.88% | |||
| Income Before Tax | 70.33% | -9.75% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 70.33% | -622.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 70.33% | -9.75% | |||
| EBIT | 75.39% | -38.88% | |||
| EBITDA | 79.22% | -42.58% | |||
| EPS Basic | 73.68% | -1.79% | |||
| Normalized Basic EPS | 71.43% | -25.00% | |||
| EPS Diluted | 73.68% | -1.79% | |||
| Normalized Diluted EPS | 74.29% | -25.00% | |||
| Average Basic Shares Outstanding | 8.64% | 9.04% | |||
| Average Diluted Shares Outstanding | 20.30% | 9.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||